A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00730847|
Recruitment Status : Terminated (GSK received exemption from PDFDA on conduct of this post-marketing surveillance (PMS) study.)
First Posted : August 8, 2008
Results First Posted : December 21, 2012
Last Update Posted : May 30, 2018
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Prevention|
Human Papillomavirus Infection Leading to Cervical Cancer
|Recruitment Details||Since this was a post-marketing study (PMS), subjects may have received one or two doses of Cervarix outside of the PMS.|
Out of 743 subjects enrolled in the study, only 596 subjects received study vaccination.
The whole set of data was not cleaned for this study. Analysis was performed on subjects with cleaned data and on subjects with missing data or unresolved data queries, or both. The overall group includes both cleaned and not cleaned data.